| Status | In progress |
| Decision | Selected |
| Process | STA 2018 |
| ID number | 3773 |
Provisional Schedule
| Expected publication | 14 September 2022 |
Project Team
| Project lead | Daniel Davies |
Email enquiries
- If you have any queries please email TATeam3@nice.org.uk
| External Assessment Group | Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
| Companies sponsors | Bayer (finerenone) |
| Others | Department of Health and Social Care |
| NHS Eastern Cheshire CCG | |
| NHS England | |
| NHS South West Lincolnshire CCG | |
| Welsh Government | |
| Patient carer groups | Kidney Care UK |
| UK Kidney Association | |
| Professional groups | Association of British Clinical Diabetologists |
| Primary Care Diabetes Society | |
| Royal College of Physicians | |
| UK Clinical Pharmacy Association | |
| Associated public health groups | None |
| Comparator companies | AstraZeneca (dapagliflozin) |
| Boehringer Ingelheim (empagliflozin) | |
| Merck Sharp & Dohme (ertugliflozin) | |
| General commentators | All Wales Therapeutic and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Welsh Kidney Patients Association | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 May 2022 - 06 June 2022 | Draft guidance |
| 14 April 2022 | Committee meeting: 1 |
| 28 June 2021 | Invitation to participate |
| 25 June 2021 | In progress. In progress |
| 03 March 2021 - 31 March 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual